BriaCell Therapeutics

BriaCell Therapeutics Corp. describes itself as a clinical-stage immuno-oncology company, with a corporate office in West Vancouver, British Columbia, and a United States office in Philadelphia; it is listed on Nasdaq (BCTX) and the Toronto Stock Exchange (BCT). Its lead candidate Bria-IMT is described by the company as a patented, off-the-shelf, cell-based targeted immunotherapy, given with an immune checkpoint inhibitor in a pivotal phase 3 study in metastatic breast cancer; the company states that the FDA granted it Fast Track status. That study, NCT06072612 (BRIA-ABC), compares the Bria-IMT regimen with a checkpoint inhibitor against treatment of the physician's choice. Bria-OTS is a platform of personalised off-the-shelf cell-based immunotherapies in a phase 1/2 study, initially in breast cancer, with prostate cancer named as the next indication. In fiscal year 2026 NCI awarded the company USD 947,870 under SBIR Phase II grant 5R44CA281555-03 for an off-the-shelf tumour cell vaccine with HLA-matching alleles for advanced metastatic prostate cancer.